Member access

4-Traders Homepage  >  Shares  >  NATIONAL STOCK EXCHANGE OF INDIA  >  Dr. Reddy's Laboratories Limited    DRREDDY   INE089A01023

End-of-day quote. End-of-day quote NATIONAL STOCK EXCHANGE OF INDIA - 10/22
3047 INR   +2.64%
6d ago DR REDDY LABORATORIES : . Reddy's to Release Q2 FY15 Results on October 29,..
10/08DJIndia Shares Edge Lower, Infosys Weighs
09/24 DR REDDY LABORATORIES : . Reddy’s Announces the Launch of LEVALBUTERO..
SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll news 

Dr. Reddy's Laboratories Limited : Dr. Reddy’s Announces the Launch of Zoledronic Acid Injection

03/05/2013 | 04:15am US/Eastern

Hyderabad, India, March 05, 2013

Dr. Reddy's Laboratories (NYSE: RDY) announced today that it has launched Zoledronic Acid Injection (4 mg/5 mL), a bioequivalent generic version of Zometa® (zoledronic acid) 4 mg/5 mL Injection in the US market on March 4, 2013, following the approval by the United States Food & Drug Administration (USFDA) of Dr. Reddy's ANDA for Zoledronic Acid Injection (4 mg/5 mL).

Dr. Reddy's Zoledronic Acid Injection 4 mg/5mL is available in a single use vial of concentrate.

This press release includes forward-looking statements, as defined in the U.S. Private Securities Litigation Reform Act of 1995. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.

About Dr. Reddy's
Dr. Reddy's Laboratories Ltd. (NYSE: RDY) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses -Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products- Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars, differentiated formulations and NCEs. Therapeutic focus is on gastro-intestinal, cardiovascular, diabetology, oncology, pain management, anti-infective and pediatrics. Major markets include India, USA, Russia and CIS, Germany, UK, Venezuela, S. Africa, Romania, and New Zealand. For more information, log on to:

Zometa® is a registered trademark of Novartis AG

For more information please contact:

Investors and Financial Analysts:
Kedar Upadhye at +91-40-66834297
Saunak Savla at +91-40-49002135
Milan Kalawadia (USA) at +1 908-203-4931

S Rajan at +91-40-49002445

distributed by
1d ago SUN PHARMACEUTICAL : Pharma, dr reddy's price scrutiny in us reaches next level
6d ago DR REDDY LABORATORIES : . Reddy's to Release Q2 FY15 Results on October 29, 2014
10/13 Drl, sun & cadila arms under us lens for soaring prices
10/08DJIndia Shares Edge Lower, Infosys Weighs
09/26 DR REDDY LABORATORIES : Launches products in us
09/24 DR REDDY LABORATORIES : . Reddy’s Announces the Launch of LEVALBUTEROL INH..
09/24 DR REDDY LABORATORIES : India's fastest growing companies: the middleweights - d..
09/19 DR REDDY LABORATORIES : -gsk pack runs into rough weather, review likely
09/12 DR REDDY LABORATORIES : Turns to local youths to operate plants
09/11 NOVARTIS : Drags drl to us court for patent violation
Duration : Period :
Dr. Reddy's Laboratories L Technical Analysis Chart | DRREDDY | INE089A01023 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes